Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Asset Writedowns and Impairment: 2019-2024

Historic Asset Writedowns and Impairment for Beauty Health (SKIN) over the last 6 years, with Dec 2024 value amounting to $28.0 million.

  • Beauty Health's Asset Writedowns and Impairment fell 65.74% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 69.11%. This contributed to the annual value of $28.0 million for FY2024, which is 53.46% up from last year.
  • Per Beauty Health's latest filing, its Asset Writedowns and Impairment stood at $28.0 million for FY2024, which was up 53.46% from $18.3 million recorded in FY2023.
  • In the past 5 years, Beauty Health's Asset Writedowns and Impairment registered a high of $28.0 million during FY2024, and its lowest value of $1.1 million during FY2021.
  • For the 3-year period, Beauty Health's Asset Writedowns and Impairment averaged around $17.2 million, with its median value being $18.3 million (2023).
  • In the last 5 years, Beauty Health's Asset Writedowns and Impairment dropped by 21.36% in 2021 and then surged by 353.62% in 2022.
  • Beauty Health's Asset Writedowns and Impairment (Yearly) stood at $1.4 million in 2020, then dropped by 21.36% to $1.1 million in 2021, then skyrocketed by 353.62% to $5.1 million in 2022, then skyrocketed by 255.21% to $18.3 million in 2023, then soared by 53.46% to $28.0 million in 2024.